Publications by authors named "M Wiesneth"
Article Synopsis
- The study investigates how seasonal changes affect nectar availability for pollinators, specifically comparing early spring with summer conditions.
- It tests two hypotheses: one suggesting consistent resource limitation throughout the seasons and another proposing more relaxed limitations in spring that become severe later.
- Results indicate lower nectar depletion in spring compared to summer, supporting the idea of a seasonal mismatch, while highlighting that factors like time of day and different flower types significantly influence nectar availability.
Hematopoietic stem cell transplantation (HSCT) from haploidentical donors is a viable option for patients lacking HLA-matched donors. Here we report the results of a prospective multicenter phase I/II trial of transplantation of TCRαβ and CD19-depleted peripheral blood stem cells from haploidentical family donors after a reduced-intensity conditioning with fludarabine, thiotepa, and melphalan. Thirty pediatric and 30 adult patients with acute leukemia (n = 43), myelodysplastic or myeloproliferative syndrome (n = 6), multiple myeloma (n = 1), solid tumors (n = 6), and non-malignant disorders (n = 4) were enrolled.
View Article and Find Full Text PDFThe efficacy of immunotherapies in cancer treatment becomes more and more apparent not only in different solid tumors but also in hematological malignancies. However, in acute myeloid leukemia (AML), mechanisms to increase the efficacy of immunotherapeutic approaches have to be further elucidated. Targeting leukemic progenitor and stem cells (LPC/LSC) by specific CTL, for instance, in an adjuvant setting or in minimal residual disease, might be an option to prevent relapse of AML or to treat MRD.
View Article and Find Full Text PDFArticle Synopsis
- - This study explores the translation of a validated pre-clinical protocol for expanding mesenchymal stromal cells (MSCs) into Good Manufacturing Practice (GMP) compliant production for clinical trials, specifically for alveolar bone reconstitution.
- - Results showed that despite variations in the starting bone marrow material, the standardized manufacturing protocol consistently produced high-quality MSCs within 21 days, meeting all necessary clinical standards.
- - The findings support the feasibility of using freshly prepared MSCs for bone regeneration in clinical applications, even over long distances between the manufacturing site and the treatment location.